Drug Dispensing Service

Durvalumab (Imfinzi®)

Program start date: September 1, 2023

This program is to support eligible patients with immunotherapy drug subsidy, hoping to reduce patients’ financial burden on drug treatment.


Application criteria: (must fulfill all of the followings)

1. Valid HKID card holder

2. Adult patients of any private hospitals or private oncology centers in Hong Kong

3. Meet the medical conditions specified by this program

Financial status: Individual monthly income not exceeding HK$ 120,000 in total


For program details and the application procedures, please contact SafeMed Dispensary (Tel: 2979 0380).